Baik, Ron http://orcid.org/0000-0002-2458-0121
Cromer, M. Kyle http://orcid.org/0000-0002-8198-5010
Glenn, Steve E.
Vakulskas, Christopher A. http://orcid.org/0000-0001-8510-4332
Chmielewski, Kay O.
Dudek, Amanda M.
Feist, William N. http://orcid.org/0000-0002-5870-4460
Klermund, Julia http://orcid.org/0000-0001-6069-8189
Shipp, Suzette
Cathomen, Toni http://orcid.org/0000-0002-7757-4630
Dever, Daniel P.
Porteus, Matthew H. http://orcid.org/0000-0002-3850-4648
Article History
Received: 23 February 2023
Accepted: 8 November 2023
First Online: 2 January 2024
Competing interests
: The authors of this study also wish to declare the following conflicts of interest: M.H.P. is a member of the scientific advisory board of Allogene Therapeutics. M.H.P. is on the Board of Directors of Graphite Bio. M.H.P. has equity in CRISPR Tx. M.K.C. and M.H.P. have equity in Graphite Bio. D.P.D. was an employee of Graphite Bio. C.A.V. and S.E.G. are employees of Integrated DNA Technologies, Inc. The remaining authors declare no competing interests.
: The works was performed on blinded samples from healthy donors of CD34+ HSPCs and inclusive of all cells that were donated to research. The research was performed, analyzed and communicated in an ethical manner.